Answers are grounded in this paper and cite their sources.
This multicenter phase II basket trial investigated the efficacy, safety, and pharmacokinetics of Debio 1347, an investigational, oral, highly selective, ATP-competitive, small molecule inhibitor of FGFR1-3, in patients with solid tumors harboring a functional FGFR1-3 fusion.
No takes yet. Share an insight, caveat, or question.
Grivas et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: